


USSN 10/812,245

Amendments to the claims

1. (original) A compound of Formula I



wherein

Ar is phenyl optionally substituted with 1-3 substituents selected from the group consisting of halogen, C<sub>1-6</sub>alkyl, and C<sub>1-6</sub>alkoxy, or Ar is 2,3-dihydrobenzofuran-4-yl;

R<sup>1</sup> is C<sub>1-6</sub>alkyl or phenyl wherein phenyl is optionally substituted with 1-3 substituents selected from the group consisting of halogen, C<sub>1-6</sub>alkyl, and C<sub>1-6</sub>alkoxy;

or Ar and R taken together with the carbon to which they are attached are 1-indanyl or 9-fluorenyl;

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, and R<sup>5</sup> are independently hydrogen, halo, C<sub>1-3</sub>alkoxy, or C<sub>1-6</sub>alkyl;

or R<sup>2</sup> and R<sup>3</sup> taken together, R<sup>3</sup> and R<sup>4</sup> taken together, or R<sup>4</sup> and R<sup>5</sup> taken together are -O(CH<sub>2</sub>)<sub>2-3</sub>- or -O(CH<sub>2</sub>)<sub>1-2</sub>O-;

R<sup>6</sup> is selected from the group consisting of hydrogen, C<sub>1-6</sub>alkyl, C<sub>3-7</sub>cycloalkyl, C<sub>1-6</sub>alkoxy, C<sub>1-2</sub>perfluoroalkyl, -CH<sub>2</sub>OC<sub>1-3</sub>alkyl, -(CH<sub>2</sub>)<sub>1-2</sub>CO<sub>2</sub>R<sup>7</sup>, -(CH<sub>2</sub>)<sub>1-2</sub>CO<sub>2</sub>NR<sup>7</sup><sub>2</sub>, -NR<sup>7</sup><sub>2</sub>, -CH<sub>2</sub>Cl, -CH<sub>2</sub>OCOMe, -CH<sub>2</sub>OPh, benzyl, 2-thienyl, 2-furanyl, 5-isoxazolyl, 4-biphenyl, naphthyl, 4-(1,2-methylenedioxy)phenyl, and phenyl where phenyl is optionally substituted with 1-3 substituents selected from halogen, C<sub>1-3</sub>alkoxy, C<sub>1-2</sub>perfluoroalkyl, C<sub>1-2</sub>perfluoroalkoxy, and nitro; and

R<sup>7</sup> is hydrogen or C<sub>1-6</sub>alkyl;

or a stereoisomer, pharmaceutically acceptable salt, or solvate thereof.

2. (original) The compound of claim 1 where Ar and R<sup>1</sup> are each phenyl optionally substituted with 1-3 substituents selected from halogen, C<sub>1-6</sub>alkyl, and C<sub>1-6</sub>alkoxy.

USSN 10/015,328

PH-7203

3. (original) The compound of claim 2 where Ar is phenyl or 4-chlorophenyl and R<sup>1</sup> is phenyl.

4. (original) The compound of claim 3 where R<sup>4</sup> is C<sub>1-3</sub> alkoxy.

5. (original) The compound of claim 4 selected from the group consisting of

1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carbaldehyde;

1-[1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-ethanone;

1-[1-(2,2-diphenyl-ethyl)-6-bromo-7-methoxy-3,4-dihydro-1H-isoquinolin-2-yl]-ethanone;

1-[1-(2,2-diphenyl-ethyl)-6-bromo-7-methoxy-3,4-dihydro-1H-isoquinolin-2-yl]-heptanone;

1-[1-(2-(4-chlorophenyl)-2-phenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-ethanone;

1-[1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-propan-1-one;

1-[1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-butan-1-one;

cyclopropyl-[1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-methanone;

[1-(

2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-phenyl-methanone;

1-[1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-2,2,2-trifluoro-ethanone;

1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid amide;

1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid methylamide;

1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid methyl ester; and

1-[1-(2,2-diphenyl-ethyl)-7-methoxy-3,4-dihydro-1H-isoquinolin-2-yl]-ethanone;


or a pharmaceutically acceptable salt or solvate thereof.

6. (original) The compound of claim 3 where R<sup>3</sup> and R<sup>4</sup> taken together are -O(CH<sub>2</sub>)<sub>2-3</sub>- or -O(CH<sub>2</sub>)<sub>1-2</sub>O-.

USSN 10/015,328

7. (cancelled)

8. (currently amended) A method of treating sleep disorders comprising the administration of a therapeutic amount of the compound of claim 7, a compound of Formula Ia



where:

Ar is phenyl optionally substituted with 1-3 substituents selected from the group consisting of halogen, C<sub>1-6</sub>alkyl, and C<sub>1-6</sub>alkoxy, or Ar is 2,3-dihydrobenzofuran-4-yl;

R<sup>1</sup> is hydrogen, C<sub>1-6</sub>alkyl, or phenyl wherein phenyl is optionally substituted with 1-3 substituents selected from the group consisting of halogen, C<sub>1-6</sub>alkyl, and C<sub>1-6</sub>alkoxy;

or Ar and R taken together with the carbon to which they are attached are 1-indanyl or 9-fluorenyl;

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, and R<sup>5</sup> are independently hydrogen, halo, C<sub>1-3</sub>alkoxy, or C<sub>1-6</sub>alkyl;

or R<sup>2</sup> and R<sup>3</sup> taken together, R<sup>3</sup> and R<sup>4</sup> taken together, or R<sup>4</sup> and R<sup>5</sup> taken together are -O(CH<sub>2</sub>)<sub>2-3</sub>- or -O(CH<sub>2</sub>)<sub>1-2</sub>O-;

R<sup>6</sup> is selected from hydrogen, C<sub>1-6</sub>alkyl, C<sub>3-7</sub>cycloalkyl, C<sub>1-6</sub>alkoxy, C<sub>1-3</sub>perfluoroalkyl, -CH<sub>2</sub>OC<sub>1-3</sub>alkyl, -(CH<sub>2</sub>)<sub>1-3</sub>CO<sub>2</sub>R<sup>7</sup>, -(CH<sub>2</sub>)<sub>1-3</sub>CO<sub>2</sub>NR<sup>7</sup>, -NR<sup>7</sup>, -CH<sub>2</sub>Cl, -CH<sub>2</sub>OCOMe, -CH<sub>2</sub>OPh, benzyl, 2-thienyl, 2-furanyl, 5-isoxazolyl, 4-biphenyl, naphthyl, 4-(1,2-methylenedioxy)phenyl, and phenyl wherein phenyl is optionally substituted with 1-3 substituents selected from the group consisting of halogen, C<sub>1-3</sub>alkoxy, C<sub>1-3</sub>perfluoroalkyl, C<sub>1-3</sub>perfluoroalkoxy, and nitro; and

R<sup>7</sup> is hydrogen or C<sub>1-6</sub>alkyl;

OCT 4 2004 2:29PM BMS PATENT 203 677 6900

NO. 085 P. 6

PH-7203

USSN 10/015,328

or a stereoisomer, pharmaceutically acceptable salt, or solvate thereof.

9. (cancelled)

10. (currently amended) A composition useful for treating a patient having sleep disorders comprising a therapeutic amount of a compound of claim 7~~8~~ and a pharmaceutically acceptable carrier.